Cell Bio Human Tech

At a glance

Cell Bio Human Tech filed 57 disclosures in the last 12 months, including 12 insider, 7 buyback, 2 5% holder, 2 issuance and 2 m&a. The most recent key filing was on Oct 21: Ended a share buyback trust contract.

Revenue for 2025 was ₩51.1B, up 79.7% on 2024. Operating margin was 18.2% against 14.2% a year earlier. Debt was 50% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩32.1B and operating profit of ₩4.9B.

The 2025 annual report lists 97 employees with an average tenure of 2.4 years and average pay of ₩58.7M, #1036 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩137M each on average. It paid no cash dividend for 2025. 이권선 and related parties held 35.63% at year end.

From the 2025 annual report

Staff: 97 (65 men, 32 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩4.8B. Directors and auditors: 6, paid ₩824M in total.

No cash dividend was paid for 2025.

Largest shareholder

이권선 holds 34.33%; with 8 related parties the group holds 35.63% of common shares at year end (from 34.11% at the start of the year).

Auditor: 이정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary